EPS Innovative Medicine (Japan) Co., Ltd. is currently engaged in the business management and support of group companies and the promotion of our research department. Specific drug candidates/technologies that we own, and their business details are as follows.
- EPS Innovative Medicine (Japan) Co., Ltd. manages and supports the business of FEF Pharmaceutical Co., Ltd., which is conducting clinical development with the aim of obtaining marketing authorization as a licensee of drug candidates/technologies originated by academia.
- EPS Innovative Medicine (Japan) Co., Ltd. manages and supports the business of EPD Co., Ltd., aiming to create a new value of brown adipocyte induction technology, originated by academia, as a licensee.
- Based on the idea that the secretory IgA affects a defense function against not only allergens of allergic diseases but also the new coronavirus, its Research Center is focusing on its significance and pursuing the possibility of sublingual vaccines.
For more information,
please feel free to contact us from below.